A Patient’s Guide to Clinical Trials
En Español | En Français
NIH Clinical Research Trials and You
Guidance regarding HIV anti-retroviral treatment in developing countries
Policy on Research Involving Human Subjects
The study is testing the safety of a vaccine for herpes simplex virus-2 (HSV-2). In the United States, HSV-2 affects approximately 16 percent of persons aged 14 to 49. HSV-2 genital infection increases the risk of getting HIV or giving it to someone else. This virus can cause severe disease in people with immature or compromised immune systems. No vaccine is currently available.
You may be eligible if you are
Study participants will have two screening visits and then 10 or more visits over the course of a year. All volunteers will be compensated for their time.
The study is being conducted at the Warren Grant Magnuson Clinical Center (Building 10) at NIH. The NIH campus is accessible by car and public transportation.
There is no charge to participate in this research study. All study-related medical care and procedures are provided free of charge.
Yes, you will be compensated for your participation in the study.
If you are interested in volunteering for this study, go to the study’s confidential online questionnaire or contact
Office of Patient Recruitment, NIH Clinical CenterToll free: 1-800-411-1222 (reference 13-I-0172)TTY: 1-866-411-1010 Se habla españolEmail: email@example.comOffice hours: 8:00 a.m.-3:30 p.m. Eastern Time
To learn more about this study (trial ID: NCT01915212), visit clinicaltrials.gov and read some frequently asked questions.
Last Updated September 08, 2014
Last Reviewed February 13, 2015